WebJan 29, 2024 · Sarepta Therapeutics. Market value: $8.3 billion TipRanks consensus price target: $203.00 (82% upside potential) TipRanks consensus rating: Strong Buy (opens in new tab) Sarepta Therapeutics (SRPT ... WebAn early-stage oncology focused biotech was planning for public listing and we supported them in crafting the IPO equity story. We synthesized key value drivers by assessing portfolio and company capabilities against peer company sets, articulated the portfolio narrative by considering scientific differentiations, competitive positioning, and …
How to Invest in Biotech - money.usnews.com
Web1 day ago · Biotech and Pharma Sarepta Stock Has $30 to $40 Upside if Panel on Gene Therapy Drug Positive, Says Analyst Apr. 4, 2024 at 12:15 p.m. ET by Barron's Sarepta Therapeutics stock initiated with buy ... WebMay 19, 2024 · The biotech sector was in focus last week with pipeline and regulatory updates from Agenus (AGEN) and Sarepta (SRPT), among others. Biotech Stock Roundup: AGEN, SRPT Surge & BIIB, REGN Provide ... crypto programs
Biotech String: Assessing the January Damage, Gilead
WebApr 10, 2024 · Sarepta Therapeutics, Inc. has a 52-week low of $61.28 and a 52-week high of $159.84. Sarepta Therapeutics ( NASDAQ:SRPT - Get Rating) last posted its earnings results on Tuesday, February 28th. The biotechnology company reported ($1.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.28) by $0.04. Web22 hours ago · With a volume of 2,235,160, the price of SRPT is down -6.46% at $128.79. RSI indicators hint that the underlying stock may be approaching oversold. Next earnings … Web1 day ago · This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth. SAREPTA THERAPEUTICS INC … crys hay cries